IntraCellular Seeks To Raise $400M Via Equity To Fund Commercialization Of Schizophrenia Med
Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering of
A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report
Pre-open movers
U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year. Investors are awaiting earnings results from SMART Global Holdings, Inc. (NASDAQ: SGH).
5 Stocks To Watch For January 4, 2022
Some of the stocks that may grab investor focus today are:
Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.
65 Biggest Movers From Yesterday
Gainers
Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index.
Analyst Ratings For Intra-Cellular Therapies
Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings:
Intra-Cellular Therapies Announces U.S. FDA Approval Of CAPLYTA For The Treatment Of Bipolar Depression in Adults
CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or
SVB Leerink Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $50
SVB Leerink analyst Marc Goodman maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and raises the price target from $45 to $50.
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours.